{
  "pmcid": "11849253",
  "sha256": "3bfabee67b84c106a7728803ee07a2d98ba97aefea21afabb7604904739a4cab",
  "timestamp_utc": "2025-11-09T15:24:49.932036+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.217268305171533,
    "reading_ease": 28.626854838709704,
    "word_count": 279
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This is a double blind, prospective randomized controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "including patients aged ≥65 years ( n = 195) admitted for routine cardiac surgery with cardiopulmonary bypass"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients in the study group received Ringer’s acetate 1000 mL + 400 mL Mannitol (60 g) + sodium chloride 40 mL (160 mmol) and heparin 2 mL (10 000 IU) 966 mOsmol ( n = 98), while patients in the control group received Ringer’s acetate 1400 mL + heparin 2 mL (10 000 IU), 388 mOsmol ( n = 97) as pump prime"
      },
      "Objective": {
        "score": 1,
        "evidence": "The study objective was to investigate whether a Ringer’s acetate based priming solution with addition of Mannitol and sodium concentrate increases the risk of cardiac surgery associated kidney injury (CSA-AKI)."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "Acute kidney injury was analysed based on the Kidney Disease Improving Outcomes (KDIGO 1-3) definition."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 2,
        "evidence": "This is a double blind, prospective randomized controlled trial"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "including patients aged ≥65 years ( n = 195)"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Six patients in the Ringer and five patients in the Mannitol group developed CSA-AKI (KDIGO 1-3)"
      },
      "Result_Outcome": {
        "score": 1,
        "evidence": "The overall incidence of CSA-AKI (KDIGO stage 1) was 2.6% on day 1 in the ICU and 5.6% on day 3, postoperatively."
      },
      "Harms": {
        "score": 1,
        "evidence": "The overall incidence of CSA-AKI (KDIGO stage 1) was 2.6% on day 1 in the ICU and 5.6% on day 3, postoperatively."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 13,
    "max_score": 25
  }
}